We found previously that selective blockade of endothelin ETA receptors is superior to nonselective ETA/ETB in attenuating hypertension and survival rate in Ren-2 transgenic rats (TGR). In the present pilot study, we were interested in whether similar effects will be found in TGR with inducible malignant hypertension (iTGR, official strain name Cyp1A1-Ren-2rats), which were derived from the original Ren-2 transgenic rat strain.